FDA Approves Relyvrio For ALS
FRIDAY, Sept. 30, 2022 -- The U.S. Food and Drug Administration on Thursday gave its approval to a new drug for amyotrophic lateral sclerosis (ALS). But approval of the drug, called Relyvrio (sodium phenylbutyrate/taurursodiol), is bound to stir new...
Read more »